Tcr2 Therapeutics Inc

NASDAQ:TCRR  
10.00
-5.72 (-36.39%)
4:16:46 PM EDT: $10.02 +0.02 (+0.20%)
Products

TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment

Published: 09/02/2021 13:27 GMT
Tcr2 Therapeutics Inc (TCRR) - Tcr² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma.